Our findings indicate that PLPP4 has the potential values as clinical markers and immunotherapeutic targets in the glioma and PAAD based on multiple large bioinformatics databases, thus providing clinicians with additional information to help them choose more appropriate drugs and more accurately assess the prognosis of the glioma and patients. The gene discussed is PLPP4; the disease is glioma.